Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment

被引：23
|
作者：
Crocq, MA [1 ]
Leclercq, P [1 ]
Guillon, MS [1 ]
Bailey, PE [1 ]
机构：
[1] Ctr Hosp, F-68250 Rouffach, France
来源：
EUROPEAN PSYCHIATRY | 2002年 / 17卷 / 05期
关键词：
olanzapine; obsessive-compulsive disorder; augmentation therapy; treatment-unresponsive OCD;
D O I：
10.1016/S0924-9338(02)00673-9
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：296 / 297
页数：2
相关论文
共 50 条
  • [1] Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study
    Pfanner, C
    Marazziti, D
    Dell'Osso, L
    Presta, S
    Gemignani, A
    Milanfranchi, A
    Cassano, GB
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2000, 15 (05) : 297 - 301
  • [2] Open-Label Study of Duloxetine for the Treatment of Obsessive-Compulsive Disorder
    Dougherty, Darin D.
    Corse, Andrew K.
    Chou, Tina
    Duffy, Amanda
    Arulpragasam, Amanda R.
    Deckersbach, Thilo
    Jenike, Michael A.
    Keuthen, Nancy J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 18 (02): : 1 - 4
  • [3] Naltrexone in Obsessive-Compulsive Disorder: an Open-Label Trial
    Hamidi, Aram
    Jahanguiri, Bijan
    Esfahani, Mehdi Nasr
    Dadfar, Mahbuobeh
    IRANIAN JOURNAL OF PSYCHIATRY AND BEHAVIORAL SCIENCES, 2007, 1 (01) : 16 - 21
  • [4] Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder
    Rosenberg, DR
    Stewart, CM
    Fitzgerald, KD
    Tawile, V
    Carroll, E
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1999, 38 (09): : 1180 - 1185
  • [5] Open-label trial of paroxetine in children with obsessive-compulsive disorder
    Diler, RS
    Avci, A
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2000, 61 (10): : 706 - 719
  • [6] Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder
    D'Amico, G
    Cedro, C
    Muscatello, MR
    Pandolfo, G
    Di Rosa, AE
    Zoccali, R
    La Torre, D
    D'Arrigo, C
    Spina, E
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (04): : 619 - 623
  • [7] Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study
    Stryjer, Rafael
    Dambinsky, Yael
    Timinsky, Igor
    Green, Tamar
    Kotler, Moshe
    Weizman, Abraham
    Spivak, Baruch
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2013, 28 (02) : 96 - 98
  • [8] Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
    Coric, V
    Taskiran, S
    Pittenger, C
    Wasylink, S
    Mathalon, DH
    Valentine, G
    Saksa, J
    Wu, YT
    Gueorguieva, R
    Sanacora, R
    Malison, RT
    Krystal, JH
    BIOLOGICAL PSYCHIATRY, 2005, 58 (05) : 424 - 428
  • [9] What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study
    Shim, Geumsook
    Park, Hye Youn
    Jang, Joon Hwan
    Kim, Euitae
    Park, Hye Yoon
    Hwang, Jae Yeon
    Kim, Sung Nyun
    Jang, Go-Eun
    Kwon, Jun Soo
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2011, 26 (05) : 284 - 290
  • [10] Refractory obsessive-compulsive disorder: a challenging treatment
    Ramos, A. L.
    Salgado, H.
    EUROPEAN PSYCHIATRY, 2022, 65 : S295 - S295
12345